Drug
YZJ-1139
YZJ-1139 is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
20%
Ph phase_1
4
80%
Phase Distribution
4
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(3)
Detailed Status
Completed3
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 14 (80.0%)
Phase 31 (20.0%)
Trials by Status
completed360%
recruiting120%
active_not_recruiting120%
Recent Activity
2 active trials
Showing 5 of 5
recruitingphase_3
Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder
NCT06975514
completedphase_1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants
NCT06673927
completedphase_1
PK/PD Study of YZJ-1139
NCT06685341
completedphase_1
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
NCT06671509
active_not_recruitingphase_1
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment
NCT06671444
Clinical Trials (5)
Showing 5 of 5 trials
NCT06975514Phase 3
Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder
NCT06673927Phase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants
NCT06685341Phase 1
PK/PD Study of YZJ-1139
NCT06671509Phase 1
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
NCT06671444Phase 1
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5